Seeking treatment for bothersome vitreous floaters is patient driven. To measure the impact of floaters and treatment on an individual's quality of life, patient-reported outcome measurements (PROMs) are essential. We review all studies using a PROM for patients with floaters. We evaluated content coverage against quality-of-life domains previously identified in other ophthalmic disorders, and against a qualitative study investigating quality-of-life issues in patients with floaters. We assessed measurement properties of PROMs using an extensive range of psychometric quality criteria. We identified 59 studies using 28 different PROMs. Many PROMs were not specifically developed for patients with floaters. Floater-specific PROMs were mostly based on content validation from an ophthalmologist or researcher perspective; two included a patient perspective. Using the outcomes of the qualitative study, we found that the floater-specific PROMs were narrow in their content coverage, with most items relating to visual symptoms and activity limitations. Testing the psychometric quality of PROMs was rare, and when employed mostly limited to responsiveness and known group validity. The remarkable high number of floater-specific PROMs reveals a need for such measurements in ophthalmology. Unfortunately, reporting on psychometric quality is limited, and content development is most often done without patient involvement.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.survophthal.2023.06.003 | DOI Listing |
Clin Ophthalmol
December 2024
Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USA.
Purpose: To report our real-world experience using intravitreal faricimab, a novel anti-vascular endothelial growth factor (anti-VEGF) therapy, in eyes with neovascular age-related macular degeneration (nAMD) previously treated with other anti-VEGF therapy.
Patients And Methods: A retrospective, single-center study of previously treated nAMD eyes treated with faricimab.
Results: In 88 eyes (73 patients), mean baseline best-corrected visual acuity (BCVA) was 20/63 (range 20/20 to CF) with mean anti-VEGF injection interval of 6.
Retina
December 2024
The Retina Clinic London, 140 Harley Street, London W1G 7LB, United Kingdom.
Purpose: Propose new terminology and evaluate the effectiveness of Therapeutic Refractive Vitrectomy (TRV) for selective removal of vitreous floaters and opacities (VFO) utilizing Standardized Kinetic Anatomical Functional Testing of VFO (SK VFO Test) and new ultra widefield (UWF) OCT imaging techniques.
Methods: Retrospective analysis. Twenty eyes underwent TRV for symptomatic VFO.
Int Med Case Rep J
December 2024
Department of Surgery, King Faisal University, Al-Ahsa, Saudi Arabia.
Purpose: To report a case of partial detachment of an inverted internal limiting membrane (ILM) flap following a successful closure of a full-thickness traumatic macular hole.
Observations: A 24-year-old male patient presented with a history of a blunt trauma and a full-thickness macular hole. Visual acuity was (20/50) then deteriorated to (20/100) prior to surgery.
BMJ Case Rep
November 2024
Glaucoma, Choithram Netralaya, Indore, Madhya Pradesh, India.
Case Rep Ophthalmol Med
November 2024
Pediatric Ophthalmology Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Vitreous cysts represent uncommon ophthalmological conditions. Most patients are asymptomatic, but a minority may experience symptoms such as floaters or blurred vision. Here, we report the case of a 2-year-old girl who was incidentally found to have a vitreous cyst in her left eye during a routine outpatient clinic visit.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!